Ipamorelin is a short synthetic pentapeptide classified as a growth-hormone secretagogue. It is widely used in research as a selective probe of the ghrelin/GHS receptor because it stimulates growth-hormone release with comparatively little effect on other pituitary hormones in model systems, making it a clean tool for isolating one signaling pathway.
What makes it notable
Its reputation for selectivity — minimal impact on cortisol or prolactin readouts in preclinical work — makes it useful for attributing observed effects specifically to GHS-receptor activation. The receptor logic is detailed in its mechanism of action, and the engineered residues responsible for that selectivity are described in its structure and synthesis article.
How it differs from GHRH analogs
Ipamorelin acts at a different receptor than releasing-hormone analogs such as sermorelin and CJC-1295 (no DAC), which is why the two classes are frequently studied together. GHRH analogs raise cyclic AMP; ipamorelin drives calcium signaling through the ghrelin receptor, so the pathways complement rather than duplicate one another.
Where it fits among secretagogues
Compared with earlier, more potent but less specific GHRPs, ipamorelin is valued for a narrower response profile, positioning it as a benchmark selective secretagogue in growth-hormone-axis studies.
Research context
Reproducible work depends on characterized material; see understanding HPLC purity, and handling of the lyophilized peptide follows the general reconstitution procedure.
Experimental questions and limitations
As a laboratory probe, ipamorelin is suited to questions about GHS-R1a activation, secretagogue selectivity, and convergence between calcium-linked and cyclic-AMP-linked pituitary pathways. It does not reproduce the full biology of endogenous ghrelin, which has broader physiological context and a distinct natural structure. Results also vary with receptor expression, cell background, assay duration, and peptide integrity. Strong designs include a same-receptor comparator, a GHRH-pathway comparator, receptor-blocking controls, and more than one downstream readout. These measures prevent a growth-hormone signal from being interpreted as proof of universal selectivity or as evidence outside the tested model. Historical descriptions of selectivity should be treated as comparative, not absolute. A compound may show fewer secondary endocrine readouts than an older secretagogue while still producing context-dependent responses in engineered cells or complex tissue models. Reporting receptor expression, comparator identity, assay duration, and analytical purity makes those comparisons reproducible and prevents a broad claim from being inferred from one endpoint.
Product page: Ipamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.